acitretin has been researched along with methotrexate in 135 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 9 (6.67) | 18.2507 |
| 2000's | 30 (22.22) | 29.6817 |
| 2010's | 70 (51.85) | 24.3611 |
| 2020's | 26 (19.26) | 2.80 |
| Authors | Studies |
|---|---|
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ | 1 |
| Ekins, S; Williams, AJ; Xu, JJ | 1 |
| Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V | 1 |
| Barber, J; Dawson, S; Kenna, JG; Paul, N; Stahl, S | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| van de Kerkhof, PC; van Dooren-Greebe, RJ | 1 |
| Larsen, FG | 1 |
| Bjerring, P; Heickendorff, L; Zachariae, H | 1 |
| Altmeyer, P; Nüchel, C | 1 |
| Kuijpers, AL; van de Kerkhof, PC; van Dooren-Greebe, JV | 1 |
| Katz, HI | 1 |
| Jacyk, WK | 1 |
| Roenigk, HH | 1 |
| Koo, J | 1 |
| Chappuis, JM; Consigli, JE; González, ME; Guidi, A; Maldonado, S; Morsino, R; Papa, M | 1 |
| Feldman, S | 1 |
| van de Kerkhof, PC | 1 |
| Bröcker, EB; Hamm, H; Hofmann, UB; Terheyden, P | 1 |
| Gordon, KB; McClure, SL; Valentine, J | 1 |
| van de Kerkhof, P | 1 |
| Kormeili, T; Lowe, NJ; Patnaik, R; Rizk, D; Yamauchi, PS | 1 |
| Lebwohl, M; Maryles, S; Rozenblit, M | 1 |
| Feldman, S; Koo, J; Lebwohl, M; Menter, A | 1 |
| Feldman, SR; Koo, J; Lebwohl, M; Menter, A | 1 |
| Feldman, SR; Margolis, DJ; Nijsten, T; Rolstad, T | 1 |
| Feldman, SR; Margolis, DJ; Nijsten, T; Rolstad, T; Stern, RS | 1 |
| Evans, C; Feldman, SR; Russell, MW | 1 |
| Cather, JC; Menter, A | 1 |
| Koo, J; Lee, E | 1 |
| Menon, K; Siu, K; Strober, BE | 1 |
| Hodulik, SG; Zeichner, JA | 1 |
| Dobrić, I; Loncarić, D; Manola, I; Pasić, A; Rados, J | 1 |
| Koo, J; Leon, A; Letsinger, J; Nguyen, A | 1 |
| Gyulai, R; Kemény, L | 1 |
| Girard, C; Guilhou, JJ | 1 |
| Bos, JD; Bossuyt, PM; de Rie, MA; deBorgie, CA; Heydendael, VM; Opmeer, BC; Spuls, PI | 1 |
| Rebora, A | 1 |
| De Jong, EM; Langewouters, AM; Van De Kerkhof, PC; Van Erp, PE | 1 |
| Daoud, L; Dhaoui, MR; Doss, N; Jaber, K; Youssef, S | 1 |
| Horn, PJ; Kalb, RE; Lowenthal, KE | 1 |
| Alegre de Miguel, V; Martínez Casimiro, L; Sánchez Carazo, JL | 1 |
| Beutner, KR; Bhushan, R; Elmets, CA; Feldman, SR; Gordon, KB; Gottlieb, A; Koo, JY; Korman, NJ; Lebwohl, M; Leonardi, CL; Menter, A; Van Voorhees, AS | 1 |
| Bowen, GM; Florell, SF; Hadley, JC; Hadley, ML; Tristani-Firouzi, P | 1 |
| Alomar, A; Barco, D; Puig, L; Vilarrasa, E | 1 |
| Di Lernia, V | 1 |
| O'Rielly, DD; Rahman, P | 1 |
| Lotti, T; Pescitelli, L; Prignano, F; Ricceri, F; Ruffo, G | 1 |
| Bagel, J; Feldman, SR; Halvorson, CR; Lapolla, W; Yentzer, BA | 1 |
| Rallis, E; Verros, CD | 1 |
| Boulinguez, S | 1 |
| Cerri, A; Colombo, L; Crespi, E; Gualandri, L; Mapelli, ET; Marconi, M; Menni, S | 1 |
| Arrue, I; Carnero, L; González-Pérez, R; Soloeta, R | 1 |
| Arcese, A; Camplone, G; Carlesimo, M; Di Russo, PP; Gamba, A; La Pietra, M; Mari, E; Orsini, D | 1 |
| Bebo, BF; Brod, BA; Callis Duffin, K; Gelfand, JM; Kalb, RE; Krueger, GG; Schleicher, SM; Shin, DB; Sperber, BR; Troxel, AB; Van Voorhees, AS; Wan, J; Weisman, JD; Yeung, H | 1 |
| Frambach, Y; Gerdes, S; Mössner, R; Philipp, S; Rotterdam, S; Weyergraf, A; Wilsmann-Theis, D | 1 |
| Handa, S; Janagond, AB; Kanwar, AJ | 1 |
| Aktürk, AS; Bayramgurler, D; Bilen, N; Cağlayan, C; Demirsoy, EO; Kıran, R; Salman, S | 1 |
| Bagel, J; Blauvelt, A; Hsu, S; Hugh, J; Lebwohl, M; Nijhawan, RI; Van Voorhees, AS; Weinberg, JM | 1 |
| Burden, AD; Burfield, L | 1 |
| Alsina-Gibert, M; Belinchón, I; Carazo, C; Carrascosa, JM; Carretero, G; Dauden, E; De la Cueva-Dobao, P; Ferrán, M; Ferrandiz, C; García-Doval, I; Gómez-García, FJ; Herrera-Ceballos, E; Jiménez-Puya, R; López-Estebaranz, JL; Rivera, R; Sánchez-Carazo, JL; Torrado, R; Vanaclocha Sebastián, F | 1 |
| Chiarolanza, I; Di Lernia, V; Ficarelli, E; Lallas, A; Possemato, N; Salvarani, C | 1 |
| Assaf, M; Ghonemy, S; Nofal, A; Nofal, E; Yosef, A | 1 |
| Brod, BA; Callis Duffin, K; Gelfand, JM; Kalb, RE; Krueger, GG; Linn, KA; Robertson, AD; Schleicher, SM; Shin, DB; Shinohara, RT; Sperber, BR; Stierstorfer, MB; Takeshita, J; Troxel, AB; Van Voorhees, AS; Wang, S; Weisman, JD | 1 |
| Akbulak, O; Akdeniz, N; Bilgili, SG; Karadag, AS; Ozkanli, S; Zemheri, E; Zenginkinet, T; Zindanci, I | 1 |
| Kirby, B; Ryan, C | 1 |
| Foley, P; Kelly, JB; Strober, BE | 1 |
| Foulkes, AC; Warren, RB | 1 |
| Abeni, D; Giannantoni, P; Paradisi, A; Tabolli, S | 1 |
| Ara, M; Gracia, T; Pastushenko, E | 1 |
| Al-Ismail, D; Anderson, E; Batul Syed, S; Burden-Teh, E; Carmichael, A; Caruana, D; Darne, S; Dolman, S; Glover, M; Helbling, I; Hughes, B; Hughes, J; Jones, V; Jury, C; Kalavala, M; Katugampola, R; Lam, ML; McPherson, T; Moore, A; Murphy, R; Natarajan, S; Richards, L; Taibjee, SM; Taylor, A; Webster, S | 1 |
| Kervarrec, T; Machet, L; Machet, MC; Nadal, M; Petrella, T | 1 |
| Frambach, Y; Gerdes, S; Jacobi, A; Mössner, R; Philipp, S; Weyergraf, AJ; Wilsmann-Theis, D | 1 |
| Biterman, H; Cohen, AD; Feldhamer, I; Freud, T; Greenberg-Dotan, S; Harman-Boehm, I; Moser, H; Polishchuk, I; Shalom, G; Zisman, D | 1 |
| Bangsgaard, N; Rørbye, C; Skov, L | 1 |
| Armstrong, AW; Blauvelt, A; Krueger, GG | 1 |
| Au, SC; Garber, C; Gottlieb, A; Plotnikova, N; Sorensen, EP | 1 |
| Arenberger, P; Bachelez, H; Barker, J; Dauden, E; de Jong, EM; Feist, E; Gisondi, P; Jacobs, A; Jobling, R; Kemény, L; Maccarone, M; Mrowietz, U; Nast, A; Ormerod, AD; Papp, KA; Paul, C; Reich, K; Rosumeck, S; Saiag, P; Smith, C; Spuls, PI; Talme, T; Thio, HB; van de Kerkhof, P; Werner, RN; Yawalkar, N | 1 |
| Bae, SH; Kim, SJ; Lee, JB; Lee, SC; Won, YH; Yun, SJ | 1 |
| Abasq, C; Aubin, F; Barbarot, S; Begon, E; Boralevi, F; Bourrat, E; Bursztejn, AC; Charbit, L; Chiaverini, C; Droitcourt, C; Hadj-Rabia, S; Lasek, A; Mahé, E; Mallet, S; Maruani, A; Mazereeuw-Hautier, J; Phan, A; Plantin, P; Souillet, AL | 1 |
| Lugo-Somolinos, A; O'Shea, PM | 1 |
| Aldredge, L; Armstrong, AW; Yamauchi, PS | 1 |
| Carpentieri, A; De Marco, IM; Loconsole, F; Loiacono, A; Pacello, L; Picconi, O | 1 |
| Lim, HW; Mehta, D | 1 |
| Alfageme Roldán, F; Bermejo Hernando, A; Calvo González, JL; Marqués Sánchez, P | 1 |
| Markham, T; O'Gorman, SM; Storan, ER | 1 |
| Chen, X; Kuang, Y; Li, J; Liu, P; Su, J; Zhang, J; Zhu, W | 1 |
| Alpsoy, E; Bulbul-Baskan, E; Ergun, T; Onsun, N; Salman, A; Saricam, MH; Sarioz, A; Seckin Gencosmanoglu, D | 1 |
| Berman, E; Cohen, AD; Eran, CB; Feldhamer, I; Freud, T; Hodak, E; Oren, S; Pavlovsky, L; Shalom, G; Ziv, M | 1 |
| Cline, A; Feldman, SR; Smith, J | 1 |
| Arenberger, P; Cetkovska, P; Dolezal, T; Fialova, J; Gkalpakiotis, S; Jircikova, J; Kojanova, M | 1 |
| Croney, S | 1 |
| An, J; Gao, X; Li, J; Li, R; Teng, X; Wang, X; Wu, J; Xia, L; Xia, Y; Zhang, D | 1 |
| Frambach, Y; Gerdes, S; Jacobi, A; Mössner, R; Philipp, S; Schill, T; Steinz, K; Weyergraf, A; Wilsmann-Theis, D | 1 |
| Addis, A; Adenubiova, E; Busard, CI; Cazzaniga, S; Cohen, AD; Feldhamer, I; Gkalpakiotis, S; Hutten, BA; Kojanova, M; Lichem, R; Naldi, L; Quehenberger, F; Spuls, PI; Stern, RS; Wolf, P | 1 |
| Dommasch, ED; Gagne, JJ; Garry, EM; Joyce, CJ; Lee, MP | 1 |
| Apfelbacher, CJ; Bauer, A; Diepgen, TL; Elsner, P; Heinrich, A; Mahler, V; Molin, S; Ofenloch, RF; Schmitt, J; von Kiedrowski, R; Weisshaar, E | 1 |
| Ho, RS; Motosko, CC; Mu, EW; Zakhem, GA | 1 |
| Abalde, T; Álvarez-López, J; Batalla, A; Cabanillas, M; Fernández-Díaz, L; Fernández-Torres, R; Flórez, Á; Fonseca, E; León, Á; Monteagudo, B; Pardavila-Riveiro, R; Rodríguez-Lojo, R; Rodríguez-Pazos, L; Salgado-Boquete, L; Seoane-Pose, MJ; Suárez-Conde, I; Valdés, F; Vázquez-Veiga, H; Zulaica, Á | 1 |
| Bewley, AP; Calzavara-Pinton, PG; Hansen, JB; Nyeland, ME; Shear, NH; Signorovitch, J | 1 |
| Ashcroft, DM; Griffiths, CEM; Jabbar-Lopez, ZK; Kleyn, CE; Mason, KJ; McElhone, K; Owen, CM; Reynolds, NJ; Smith, CH; Warren, RB; Williams, S; Wilson, N; Yiu, ZZN | 1 |
| Abdollahimajd, F; Baradaran-Rafii, A; Ghalamkarpour, F; Rudolph, RI; Sadoughi, MM; Younespour, S; Zargari, O | 1 |
| Baran, R; Chiheb, S; Daniel, CR; Di Chiacchio, N; Gregoriou, S; Grover, C; Haneke, E; Iorizzo, M; Pasch, M; Piraccini, BM; Rich, P; Richert, B; Rigopoulos, D; Rompoti, N; Rubin, AI; Singal, A; Starace, M; Tosti, A; Triantafyllopoulou, I; Zaiac, M | 1 |
| Girolomoni, G; Gisondi, P; Mattiucci, A; Tonin, B | 1 |
| Cho, S; Lee, H | 1 |
| Carrascosa, JM; Daudén, E; Guisado, C; Puig, L; Sulleiro, S | 1 |
| Baran, A; Flisiak, I; Kiluk, P; Maciaszek, M; Świderska, M | 1 |
| Arnone, M; Bernardo, WM; Carvalho, AVE; Takahashí, MDF | 1 |
| Bulut, H; Engin, B; Gökalp, E; Kutlubay, Z; Özkoca, D; Serdaroğlu, S; Songür, A; Tanakol, A; Tüzün, Y; Vehid, HE | 1 |
| Gabriel, A; Gogler-Piglowska, A; Kupczak, M; Michalski, M; Mielanczyk, A; Mielanczyk, Ł; Mrowiec, K; Neugebauer, D; Scieglinska, D; Skonieczna, M | 1 |
| Montanez-Wiscovich, ME; Shivers, L | 1 |
| Armstrong, AW; Connor, C; Cordoro, KM; Davis, DMR; Elewski, BE; Elmets, CA; Gelfand, JM; Gordon, KB; Gottlieb, AB; Hariharan, V; Kaplan, DH; Kavanaugh, A; Kiselica, M; Kivelevitch, D; Korman, NJ; Kroshinsky, D; Lebwohl, M; Leonardi, CL; Lichten, J; Lim, HW; Mehta, NN; Menter, A; Paller, AS; Parra, SL; Pathy, AL; Prater, EF; Rahimi, RS; Rupani, RN; Siegel, M; Stoff, B; Strober, BE; Tapper, EB; Wong, EB; Wu, JJ | 1 |
| Kromer, C; Lippert, U; Mössner, R; Schön, MP | 1 |
| Brenaut, É | 1 |
| Villani, AP | 1 |
| Annunziata, MC; Apalla, Z; Carrera, C; Fabbrocini, G; Fattore, D; Giacchero, D; Lallas, A; Lallas, K; Lazaridou, E; Nikolaou, V; Ortiz-Brugués, A; Patri, A; Peris, K; Riganti, J; Rigopoulos, D; Romano, MC; Rossi, E; Sibaud, V; Sollena, P; Stratigos, AJ; Voudouri, D | 1 |
| Chavan, D; Jamale, V; Kale, M; Nikam, B; Shah, S | 1 |
| Andersson, NW; Simonsen, AB; Thomsen, SF; Zachariae, C | 1 |
| Ahn, KJ; Cho, YA; Choe, YB; Hong, JR; Hong, JY; Jeong, H; Kim, H; Kim, SM; Lee, YW; Yang, HS | 1 |
| Chat, VS; Han, G; Kearns, DG; Uppal, SK; Wu, JJ | 1 |
| Barker, JN; Mahil, SK; Raharja, A | 1 |
| Chanprapaph, K; Iamsumang, W; Pinyowiwat, P; Rattanakaemakorn, P; Suchonwanit, P | 1 |
| Aylı, M; Caliskan, E; Coban, SN; Esme, P; Ugur, B | 1 |
| Capalbo, E; Cartocci, A; Cinotti, E; Cortonesi, G; Orsini, C; Rubegni, P; Trovato, E | 1 |
| Ariane, M; Mahé, E | 1 |
| Chen, M; Dong, Z; Du, Y; Wang, F; Yan, Q | 1 |
| Hsieh, CY; Tsai, TF | 1 |
| Aubert, H; Balguerie, X; Barbarot, S; Barthélémy, H; Beauchet, A; Boralevi, F; Di Lernia, V; Girard, C; Hadj-Rabia, S; Mahé, E; Mallet, S; Martin, L; Mazereeuw-Hautier, J; Phan, A; Phan, C; Piram, M; Severino-Freire, M; Zitouni, J | 1 |
| Carrascosa, JM | 1 |
| Alabas, OA; Bewley, A; Griffiths, CEM; Hampton, PJ; Laws, PM; Lunt, M; Mason, KJ; Owen, CM; Reynolds, NJ; Smith, CH; Warren, RB; Yiu, ZZN | 1 |
| Chang, YC; Chen, CB; Chen, WT; Chung, WH; Hui, RC; Wang, CW; Wang, CY | 1 |
42 review(s) available for acitretin and methotrexate
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Pharmacokinetics of etretinate and acitretin with special reference to treatment of psoriasis.
Topics: Absorption; Acitretin; Etretinate; Humans; Methotrexate; Psoriasis; Vitamin A | 1994 |
[Systemic therapy of psoriasis].
Topics: Acitretin; Cyclosporine; Dermatologic Agents; Fumarates; Glucocorticoids; Humans; Immunosuppressive Agents; Keratolytic Agents; Methotrexate; Photochemotherapy; Phototherapy; Psoriasis | 1996 |
Failure of combination therapy with acitretin and cyclosporin A in 3 patients with erythrodermic psoriasis.
Topics: Acitretin; Aged; Aged, 80 and over; Calcitriol; Cyclosporine; Dermatitis, Exfoliative; Dermatologic Agents; Drug Combinations; Humans; Immunosuppressive Agents; Keratolytic Agents; Male; Methotrexate; Middle Aged; Prognosis; Psoriasis | 1997 |
Combined topical calcipotriene ointment 0.005% and various systemic therapies in the treatment of plaque-type psoriasis vulgaris: review of the literature and results of a survey sent to 100 dermatologists.
Topics: Acitretin; Administration, Topical; Calcitriol; Combined Modality Therapy; Cyclosporine; Dermatologic Agents; Drug Synergism; Drug Therapy, Combination; Etretinate; Humans; Immunosuppressive Agents; Keratolytic Agents; Methotrexate; Ointments; Phototherapy; Psoriasis; Risk; Safety; Treatment Outcome | 1997 |
Acitretin combination therapy.
Topics: Acitretin; Combined Modality Therapy; Cyclosporine; Drug Therapy, Combination; Humans; Keratolytic Agents; Methotrexate; Psoriasis; PUVA Therapy; Ultraviolet Therapy | 1999 |
Systemic sequential therapy of psoriasis: a new paradigm for improved therapeutic results.
Topics: Acitretin; Cyclosporine; Drug Administration Schedule; Drug Therapy, Combination; Humans; Keratolytic Agents; Methotrexate; Psoriasis | 1999 |
Advances in psoriasis treatment.
Topics: Acitretin; Administration, Topical; Anthralin; Anti-Inflammatory Agents; Coal Tar; Cyclosporine; Dermatologic Agents; Glucocorticoids; Humans; Methotrexate; Nicotinic Acids; Patient Education as Topic; Phototherapy; Psoriasis; PUVA Therapy; Quality of Life; Social Support; Triamcinolone | 2000 |
Therapeutic strategies: rotational therapy and combinations.
Topics: Acitretin; Administration, Topical; Anti-Inflammatory Agents; Autoimmune Diseases; Calcitriol; Dermatologic Agents; Drug Administration Schedule; Drug Therapy, Combination; Fumarates; Glucocorticoids; Humans; Immunosuppressive Agents; Keratolytic Agents; Methotrexate; Phototherapy; Psoriasis; PUVA Therapy | 2001 |
Comparative tolerability of systemic treatments for plaque-type psoriasis.
Topics: Acitretin; Cyclosporine; Dermatologic Agents; Drug Combinations; Eye Diseases; Humans; Keratolytic Agents; Liver Cirrhosis; Lymphoproliferative Disorders; Methotrexate; Nausea; Pancytopenia; Pneumonia; Pruritus; Psoriasis; PUVA Therapy; Skin Neoplasms | 2002 |
Vitamin D and systemic therapy.
Topics: Acitretin; Administration, Oral; Administration, Topical; Calcitriol; Clinical Trials as Topic; Cyclosporine; Dermatologic Agents; Drug Therapy, Combination; Humans; Keratolytic Agents; Methotrexate; Ointments; Psoriasis | 2002 |
Current systemic therapies for psoriasis: where are we now?
Topics: Acitretin; Antineoplastic Agents; Cyclosporine; Dermatologic Agents; Drug Therapy, Combination; Humans; Hydroxyurea; Keratolytic Agents; Methotrexate; Psoriasis; Remission Induction | 2003 |
Transition from methotrexate and cyclosporine to other therapies including retinoids, ultraviolet light and biologic agents in the management of patients with psoriasis.
Topics: Acitretin; Cyclosporine; Drug Therapy, Combination; Etretinate; Humans; Immunosuppressive Agents; Keratolytic Agents; Methotrexate; Phototherapy; Psoriasis; Recombinant Fusion Proteins; Treatment Outcome | 2003 |
Combination therapy to treat moderate to severe psoriasis.
Topics: Acitretin; Calcitriol; Drug Therapy, Combination; Humans; Methotrexate; Psoriasis; PUVA Therapy | 2004 |
Combining traditional agents and biologics for the treatment of psoriasis.
Topics: Acitretin; Adalimumab; Alefacept; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Biological Products; Clinical Trials as Topic; Cyclosporine; Dermatologic Agents; Drug Therapy, Combination; Etanercept; Humans; Immunoglobulin G; Infliximab; Methotrexate; Psoriasis; PUVA Therapy; Receptors, Tumor Necrosis Factor; Recombinant Fusion Proteins | 2005 |
Conventional systemic agents for psoriasis. A systematic review.
Topics: Acitretin; Clinical Trials as Topic; Cyclosporine; Drug Therapy, Combination; Evidence-Based Medicine; Humans; Hydroxyurea; Immunosuppressive Agents; Methotrexate; Practice Guidelines as Topic; Psoriasis; Thioguanine; Treatment Outcome | 2006 |
An attempt to formulate an evidence-based strategy in the management of moderate-to-severe psoriasis: a review of the efficacy and safety of biologics and prebiologic options.
Topics: Acitretin; Adalimumab; Alefacept; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Biological Products; Biological Therapy; Dermatologic Agents; Evidence-Based Medicine; Humans; Methotrexate; Psoriasis; PUVA Therapy; Randomized Controlled Trials as Topic; Recombinant Fusion Proteins | 2007 |
[The immunology of psoriasis: from basic research to the bedside].
Topics: Acitretin; Adrenal Cortex Hormones; Alefacept; Anthralin; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Autoimmunity; Biomedical Research; Cell Differentiation; Cell Proliferation; Cyclosporine; Dermatologic Agents; Humans; Immunity, Cellular; Immunosuppressive Agents; Infliximab; Keratinocytes; Keratolytic Agents; Methotrexate; Psoriasis; Recombinant Fusion Proteins; T-Lymphocytes, Regulatory; Ultraviolet Therapy | 2006 |
[Psoriasis].
Topics: Acitretin; Adrenal Cortex Hormones; Adult; Age Factors; Arthritis, Psoriatic; Calcitriol; Child; Cyclosporine; Dermatologic Agents; Diagnosis, Differential; HIV Infections; Humans; Infant; Infant, Newborn; Keratolytic Agents; Methotrexate; Ointments; Phototherapy; Psoriasis; Skin; Time Factors; Vitamins | 2006 |
[Long-term control of psoriasis is necessary].
Topics: Acitretin; Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Arthritis, Psoriatic; Biological Products; Combined Modality Therapy; Comorbidity; Cyclosporine; Cytokines; Dermatologic Agents; Humans; Immunosuppressive Agents; Infliximab; Methotrexate; Middle Aged; Psoriasis; PUVA Therapy; Quality of Life; Recurrence | 2008 |
Treatment of acrodermatitis continua of Hallopeau with TNF-blocking agents: case report and review.
Topics: Acitretin; Acrodermatitis; Adalimumab; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Betamethasone; Clobetasol; Cyclosporine; Drug Therapy, Combination; Etanercept; Female; Humans; Immunoglobulin G; Methotrexate; Mycophenolic Acid; Nails; Paronychia; Psoriasis; Receptors, Tumor Necrosis Factor; Tumor Necrosis Factor Inhibitors | 2010 |
Pharmacogenetics of psoriasis.
Topics: Acitretin; Adrenal Cortex Hormones; Antibodies, Monoclonal; Cyclosporine; Genetic Predisposition to Disease; Humans; Methotrexate; Pharmacogenetics; Precision Medicine; Psoriasis | 2011 |
A review of phototherapy protocols for psoriasis treatment.
Topics: Acitretin; Carotid Stenosis; Clinical Protocols; Humans; Immunosuppressive Agents; Keratolytic Agents; Lasers, Excimer; Methotrexate; Psoriasis; PUVA Therapy; Treatment Outcome; Ultraviolet Therapy | 2011 |
From the Medical Board of the National Psoriasis Foundation: The risk of cardiovascular disease in individuals with psoriasis and the potential impact of current therapies.
Topics: Acitretin; Antibodies, Monoclonal, Humanized; Biological Therapy; Cardiovascular Diseases; Cyclosporine; Humans; Immunosuppressive Agents; Keratolytic Agents; Methotrexate; Mycophenolic Acid; Psoriasis; PUVA Therapy; Tumor Necrosis Factor-alpha; Ustekinumab | 2014 |
Psoriasis.
Topics: Acitretin; Administration, Topical; Cardiovascular Diseases; Cyclosporine; Dermatologic Agents; Humans; Methotrexate; Phototherapy; Psoriasis; Tumor Necrosis Factor-alpha | 2013 |
Psoriasis is a systemic disease with multiple cardiovascular and metabolic comorbidities.
Topics: Acitretin; Adipokines; Alcoholism; Antibodies, Monoclonal, Humanized; Cardiovascular Diseases; Comorbidity; Cyclosporine; Dermatologic Agents; Diabetes Mellitus; Fumarates; Humans; Immunosuppressive Agents; Inflammation; Metabolic Syndrome; Methotrexate; Obesity; Psoriasis; Risk Factors; Smoking; Tumor Necrosis Factor-alpha; Ustekinumab | 2015 |
Current and future oral systemic therapies for psoriasis.
Topics: Acitretin; Anti-Inflammatory Agents, Non-Steroidal; Antimetabolites; Cyclosporine; Fumarates; Humans; Hydroxyurea; Immunosuppressive Agents; Isoxazoles; Keratolytic Agents; Leflunomide; Methotrexate; Mycophenolic Acid; Piperidines; Protein Kinase Inhibitors; Psoriasis; Pyrimidines; Pyrroles; Sulfasalazine; Thalidomide; Thioguanine | 2015 |
Pharmacogenomics and the resulting impact on psoriasis therapies.
Topics: Acitretin; Cyclosporine; Cytokines; HLA-C Antigens; Humans; Immunosuppressive Agents; Inflammation; Keratolytic Agents; Methotrexate; Pharmacogenetics; Phototherapy; Polymorphism, Genetic; Precision Medicine; Psoriasis; Research Design; Tumor Necrosis Factor-alpha | 2015 |
Etanercept combined with systemic drugs or phototherapy for treatment of psoriasis.
Topics: Acitretin; Antirheumatic Agents; Clinical Trials as Topic; Cyclosporine; Drug Therapy, Combination; Etanercept; Humans; Methotrexate; Multicenter Studies as Topic; Prospective Studies; Psoriasis; Treatment Outcome; Ultraviolet Therapy | 2015 |
Treating Psoriasis During Pregnancy: Safety and Efficacy of Treatments.
Topics: Acitretin; Administration, Cutaneous; Adrenal Cortex Hormones; Calcineurin Inhibitors; Calcitriol; Coal Tar; Contraindications; Cyclosporine; Dermatologic Agents; Female; Humans; Immunosuppressive Agents; Methotrexate; Nicotinic Acids; Pregnancy; Pregnancy Complications; Psoriasis; PUVA Therapy; Tumor Necrosis Factor-alpha; Ultraviolet Therapy; Ustekinumab | 2015 |
Managing Patients With Psoriasis in the Busy Clinic: Practical Tips for Health Care Practitioners.
Topics: Acitretin; Anti-Inflammatory Agents, Non-Steroidal; Biological Products; Cyclosporine; Disease Progression; Humans; Immunosuppressive Agents; Insurance, Health, Reimbursement; Keratolytic Agents; Medication Adherence; Methotrexate; Psoriasis; Symptom Flare Up; Thalidomide | 2016 |
Ultraviolet B Phototherapy for Psoriasis: Review of Practical Guidelines.
Topics: Acitretin; Administration, Topical; Combined Modality Therapy; Contraindications; Dermatologic Agents; Dose-Response Relationship, Radiation; Humans; Interleukin-17; Keratolytic Agents; Lasers, Excimer; Low-Level Light Therapy; Methotrexate; Phosphodiesterase Inhibitors; Practice Guidelines as Topic; Psoriasis; PUVA Therapy; Skin; Tumor Necrosis Factor-alpha; Ultraviolet Therapy | 2016 |
Advances in Psoriasis.
Topics: Acitretin; Administration, Topical; Adrenal Cortex Hormones; Cyclosporine; Dermatologic Agents; Humans; Interleukins; Methotrexate; Phototherapy; Psoriasis; PUVA Therapy; Tumor Necrosis Factor-alpha; Vitamin D | 2017 |
Infertility and teratogenicity after paternal exposure to systemic dermatologic medications: A systematic review.
Topics: Acitretin; Adrenal Cortex Hormones; Colchicine; Cyclophosphamide; Dermatologic Agents; Doxycycline; Finasteride; Humans; Infertility, Male; Isotretinoin; Male; Methotrexate; Paternal Exposure; Teratogenesis; Tetracycline; Thalidomide | 2019 |
Persistence and effectiveness of nonbiologic systemic therapies for moderate-to-severe psoriasis in adults: a systematic review.
Topics: Acitretin; Adult; Cyclosporine; Dermatologic Agents; Drug Therapy, Combination; Fumarates; Humans; Methotrexate; Multicenter Studies as Topic; Observational Studies as Topic; Psoriasis; Severity of Illness Index; Treatment Outcome | 2019 |
Secukinumab (Cosentyx°) and plaque psoriasis.
Topics: Acitretin; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Cyclosporine; Etanercept; Humans; Immunosuppressive Agents; Keratolytic Agents; Methotrexate; Psoriasis; PUVA Therapy; Severity of Illness Index; Treatment Failure; Tumor Necrosis Factor-alpha; Ultraviolet Therapy | 2017 |
Recommendations for the definition, evaluation, and treatment of nail psoriasis in adult patients with no or mild skin psoriasis: A dermatologist and nail expert group consensus.
Topics: Acitretin; Administration, Oral; Administration, Topical; Adult; Aged; Biological Products; Consensus; Cyclosporine; Dermatologic Agents; Disease Management; Expert Testimony; Female; Humans; Injections, Intralesional; Male; Methotrexate; Middle Aged; Nail Diseases; Practice Guidelines as Topic; Psoriasis; Recurrence; Risk Assessment; Severity of Illness Index; Treatment Outcome | 2019 |
Moderate to severe plaque psoriasis - treatment with drugs of the classic scheme.
Topics: Acitretin; Antibodies, Monoclonal; Brazil; Clinical Decision-Making; Cyclosporine; Dermatologic Agents; Humans; Immunosuppressive Agents; Methotrexate; Psoriasis; Severity of Illness Index; Time Factors; Treatment Outcome | 2019 |
Translating the 2020 AAD-NPF Guidelines of Care for the Management of Psoriasis With Systemic Nonbiologics to Clinical Practice.
Topics: Acitretin; Adult; Cyclosporine; Humans; Methotrexate; Psoriasis; United States | 2021 |
Efficacy of adalimumab in pediatric generalized pustular psoriasis: case series and literature review.
Topics: Acitretin; Acute Disease; Adalimumab; Adult; Child; Chronic Disease; Humans; Methotrexate; Psoriasis; Skin Diseases, Vesiculobullous | 2022 |
Management of Coexisting Bullous Pemphigoid and Psoriasis: A Review.
Topics: Acitretin; Adrenal Cortex Hormones; Anti-Bacterial Agents; Azathioprine; Biological Factors; Biological Products; Cyclosporins; Dermatologic Agents; Etanercept; Humans; Immunosuppressive Agents; Methotrexate; Niacinamide; Pemphigoid, Bullous; Psoriasis; Rituximab; Ustekinumab; Vitamins | 2022 |
Pharmacogenomics on the Treatment Response in Patients with Psoriasis: An Updated Review.
Topics: Acitretin; Endonucleases; Humans; Methotrexate; Pharmacogenetics; Psoriasis; Tumor Necrosis Factor Inhibitors | 2023 |
4 trial(s) available for acitretin and methotrexate
| Article | Year |
|---|---|
The added therapeutic efficacy and safety of alefacept in combination with other (systemic) anti-psoriatics in refractory psoriasis.
Topics: Acitretin; Adult; Aged; Alefacept; Cyclosporine; Dermatologic Agents; Drug Therapy, Combination; Female; Humans; Male; Methotrexate; Middle Aged; Psoriasis; Recombinant Fusion Proteins; Treatment Outcome | 2006 |
A global approach to psoriatic patients through PASI score and Skindex-29.
Topics: Acitretin; Adalimumab; Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Cyclosporine; Dermatologic Agents; Diagnostic Self Evaluation; Emotions; Etanercept; Female; Folic Acid; Humans; Immunoglobulin G; Immunosuppressive Agents; Infliximab; Interpersonal Relations; Male; Methotrexate; Middle Aged; Psoriasis; PUVA Therapy; Quality of Life; Receptors, Tumor Necrosis Factor; Severity of Illness Index; Surveys and Questionnaires; Treatment Outcome | 2011 |
Efficacy and safety of systemic methotrexate vs. acitretin in psoriasis patients with significant palmoplantar involvement: a prospective, randomized study.
Topics: Acitretin; Adolescent; Adult; Foot; Hand; Humans; Immunosuppressive Agents; Keratolytic Agents; Methotrexate; Middle Aged; Prospective Studies; Psoriasis; Treatment Outcome; Young Adult | 2013 |
Safety and efficacy profile of oral cyclosporine vs oral methotrexate vs oral acitretin in palmoplantar psoriasis: A hospital based prospective investigator blind randomized controlled comparative study.
Topics: Acitretin; Cyclosporine; Hospitals; Humans; Methotrexate; Prospective Studies; Psoriasis; Quality of Life; Severity of Illness Index; Treatment Outcome | 2021 |
89 other study(ies) available for acitretin and methotrexate
| Article | Year |
|---|---|
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Developing structure-activity relationships for the prediction of hepatotoxicity.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Humans; Structure-Activity Relationship; Tetracyclines; Thiophenes | 2010 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
FDA-approved drug labeling for the study of drug-induced liver injury.
Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Design; Drug Labeling; Drug-Related Side Effects and Adverse Reactions; Humans; Pharmaceutical Preparations; Reproducibility of Results; United States; United States Food and Drug Administration | 2011 |
In vitro inhibition of the bile salt export pump correlates with risk of cholestatic drug-induced liver injury in humans.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Bile Acids and Salts; Cell Line; Chemical and Drug Induced Liver Injury; Cholestasis; Drug-Related Side Effects and Adverse Reactions; Humans; Insecta; Rats; Risk Factors | 2012 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Extensive extraspinal hyperostoses after long-term oral retinoid treatment in a patient with pityriasis rubra pilaris.
Topics: Acetabulum; Acitretin; Adolescent; Adult; Azathioprine; Child; Etretinate; Exostoses; Femur Neck; Follow-Up Studies; Humans; Hyperostosis; Male; Methotrexate; Pityriasis Rubra Pilaris; Retinoids; Tretinoin | 1995 |
Plasma endothelin in psoriasis: possible relations to therapy and toxicity.
Topics: Acitretin; Cyclosporine; Endothelins; Humans; Hydroxyurea; Keratolytic Agents; Methotrexate; Psoriasis; Ranitidine | 1996 |
Pityriasis rubra pilaris in black South Africans.
Topics: Acitretin; Adolescent; Adult; Age of Onset; Black People; Child; Child, Preschool; Dermatologic Agents; Disease Progression; Emollients; Female; Humans; Infant; Keratolytic Agents; Male; Methotrexate; Middle Aged; Pityriasis Rubra Pilaris; Prospective Studies; South Africa; Treatment Outcome; Treatment Refusal | 1999 |
Generalized eruptive keratoacanthoma (Grzybowski variant).
Topics: Acitretin; Dermatologic Agents; Facies; Humans; Interferon alpha-2; Interferon-alpha; Keratoacanthoma; Male; Methotrexate; Middle Aged; PUVA Therapy; Recombinant Proteins; Skin Diseases, Papulosquamous; Treatment Failure | 2000 |
[Erythroderma after corticosteroid withdrawal in papulosquamous dermatosis in children. Diagnosis: pityriasis rubra pilaris, classic juvenile type].
Topics: Acitretin; Adult; Age Factors; Anti-Inflammatory Agents; Child, Preschool; Dermatitis, Exfoliative; Dermatologic Agents; Diagnosis, Differential; Female; Humans; Keratolytic Agents; Methotrexate; Pityriasis Rubra Pilaris; Prednisolone; PUVA Therapy; Retinoids; Substance Withdrawal Syndrome | 2001 |
Case studies in severe psoriasis: A clinical strategy.
Topics: Acitretin; Adolescent; Adult; Aged; Algorithms; Dermatologic Agents; Drug Therapy, Combination; Etretinate; Female; Health Surveys; Humans; Keratolytic Agents; Male; Methotrexate; Middle Aged; Psoriasis; Recombinant Fusion Proteins; Severity of Illness Index; Treatment Outcome; Ultraviolet Therapy | 2003 |
Systemic therapy does not usually clear psoriasis, but treatment success does not require clearing.
Topics: Acitretin; Cyclosporine; Female; Ficusin; Humans; Immunosuppressive Agents; Keratolytic Agents; Male; Methotrexate; Middle Aged; Patient Satisfaction; Photosensitizing Agents; Psoriasis; PUVA Therapy; Treatment Outcome | 2005 |
Traditional systemic treatments have not fully met the needs of psoriasis patients: results from a national survey.
Topics: Acitretin; Adult; Aged; Cyclosporine; Dermatologic Agents; Female; Ficusin; Health Surveys; Humans; Male; Methotrexate; Middle Aged; Patient Satisfaction; Psoriasis; PUVA Therapy; Treatment Outcome; United States | 2005 |
Systemic treatment for moderate to severe psoriasis: estimates of failure rates and direct medical costs in a north-eastern US managed care plan.
Topics: Acitretin; Adult; Costs and Cost Analysis; Cyclosporine; Dermatologic Agents; Female; Health Care Costs; Humans; Male; Managed Care Programs; Methotrexate; Middle Aged; New England; Phototherapy; Psoriasis; PUVA Therapy; Treatment Failure; United States | 2005 |
Modern modified 'ultra' Goeckerman therapy: a PASI assessment of a very effective therapy for psoriasis resistant to both prebiologic and biologic therapies.
Topics: Acitretin; Anthralin; Calcitriol; Coal Tar; Combined Modality Therapy; Female; Humans; Keratolytic Agents; Male; Methotrexate; Middle Aged; Nicotinic Acids; Phototherapy; Psoriasis; Salicylic Acid; Severity of Illness Index; Time Factors; Ultraviolet Therapy | 2005 |
Combination therapy with acitretin for psoriasis.
Topics: Acitretin; Adult; Alefacept; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Drug Therapy, Combination; Etanercept; Female; Humans; Immunoglobulin G; Keratolytic Agents; Male; Methotrexate; Psoriasis; PUVA Therapy; Receptors, Tumor Necrosis Factor; Recombinant Fusion Proteins; Severity of Illness Index | 2006 |
Folliculotropic mycosis fungoides with follicular mucinosis--case report.
Topics: Acitretin; Adrenal Cortex Hormones; Aged; Fatal Outcome; Humans; Male; Methotrexate; Mucinosis, Follicular; Mycosis Fungoides; PUVA Therapy; Skin Neoplasms | 2006 |
Patients with moderate-to-severe plaque psoriasis preferred oral therapies to phototherapies: a preference assessment based on clinical scenarios with trade-off questions.
Topics: Acitretin; Administration, Oral; Adult; Cyclosporine; Dermatologic Agents; Female; Humans; Keratolytic Agents; Male; Methotrexate; Patient Satisfaction; Psoriasis; PUVA Therapy; Surveys and Questionnaires; Treatment Outcome; Ultraviolet Therapy | 2007 |
Conventional therapies for psoriasis.
Topics: Acitretin; Cyclosporine; Dermatologic Agents; Drug Therapy, Combination; Humans; Italy; Keratolytic Agents; Methotrexate; Psoriasis; Randomized Controlled Trials as Topic; Treatment Outcome | 2007 |
[Management of severe psoriasis: about 50 cases].
Topics: Acitretin; Adolescent; Adult; Aged; Arthritis, Psoriatic; Child; Dermatitis, Exfoliative; Female; Follow-Up Studies; Humans; Keratolytic Agents; Male; Methotrexate; Middle Aged; Psoriasis; PUVA Therapy; Quality of Life; Retinoids; Retrospective Studies; Treatment Outcome | 2007 |
Concurrent use of methotrexate and acitretin revisited.
Topics: Acitretin; Adolescent; Adult; Aged; Alcohol Drinking; Alopecia; Chemical and Drug Induced Liver Injury; Child; Contraindications; Dermatologic Agents; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Liver Function Tests; Male; Methotrexate; Middle Aged; Psoriasis; Retrospective Studies; Treatment Outcome | 2008 |
Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics.
Topics: Acitretin; Alefacept; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Arthritis, Psoriatic; Biological Products; Cardiovascular Diseases; Cyclosporine; Depression; Etanercept; Humans; Immunoglobulin G; Interleukin-12; Interleukin-23; Lymphoma; Metabolic Syndrome; Methotrexate; Obesity; Psoriasis; PUVA Therapy; Receptors, Tumor Necrosis Factor; Recombinant Fusion Proteins; Smoking; Tumor Necrosis Factor-alpha | 2008 |
Case series of multiple recurrent reactive keratoacanthomas developing at surgical margins.
Topics: Acitretin; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Squamous Cell; Female; Fluorouracil; Forearm; Humans; Injections, Intralesional; Keratoacanthoma; Keratolytic Agents; Male; Methotrexate; Recurrence; Skin Neoplasms | 2009 |
Childhood psoriasis: often favorable outcome.
Topics: Acitretin; Administration, Topical; Anthralin; Calcitriol; Child; Cyclosporine; Dermatologic Agents; Emollients; Etanercept; Humans; Immunoglobulin G; Immunosuppressive Agents; Methotrexate; Nicotinic Acids; Plant Extracts; Psoriasis; Receptors, Tumor Necrosis Factor; Salicylates; Steroids; Tars; Treatment Outcome; Ultraviolet Therapy | 2009 |
Treatment of psoriasis in patients with hepatitis C virus infection.
Topics: Acitretin; Antiviral Agents; Cyclosporine; Drug Eruptions; Hepatitis C, Chronic; Humans; Immunosuppressive Agents; Interferon-alpha; Methotrexate; Psoriasis; Ribavirin | 2011 |
Ustekinumab treats psoriasis refractory to seven conventional and biologic therapies.
Topics: Acitretin; Adalimumab; Adrenal Cortex Hormones; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Calcitriol; Cyclosporine; Dermatologic Agents; Drug Therapy, Combination; Etanercept; Female; Humans; Immunoglobulin G; Infliximab; Methotrexate; Psoriasis; Receptors, Tumor Necrosis Factor; Tacrolimus; Treatment Outcome; Ustekinumab | 2011 |
[News on psoriasis from the 2010 Dermatology Days in Paris].
Topics: Acitretin; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Arthritis, Psoriatic; Cyclosporine; Dermatologic Agents; Dermatology; Drug Therapy, Combination; Etanercept; Evidence-Based Medicine; Humans; Immunoglobulin G; Methotrexate; Practice Guidelines as Topic; Psoriasis; Randomized Controlled Trials as Topic; Receptors, Tumor Necrosis Factor; Treatment Outcome; Ustekinumab | 2011 |
Superimposed linear psoriasis: low effectiveness of biologic therapy.
Topics: Acitretin; Aged; Antirheumatic Agents; Arthritis, Psoriatic; Biological Therapy; Cyclosporine; Etanercept; Humans; Immunoglobulin G; Immunosuppressive Agents; Loss of Heterozygosity; Male; Methotrexate; Psoriasis; Receptors, Tumor Necrosis Factor | 2011 |
[Multiple warts appearing exclusively on psoriasis plaques].
Topics: Acitretin; Adrenal Cortex Hormones; Alphapapillomavirus; Human papillomavirus 6; Humans; Immunoglobulin A; Immunosuppressive Agents; Keratolytic Agents; Male; Methotrexate; Middle Aged; Papillomavirus Infections; Paraproteinemias; Psoriasis; Remission Induction; Ultraviolet Therapy; Warts | 2011 |
Nodular melanoma arising in a patient treated with anti-tumor necrosis factor alpha antagonists.
Topics: Acitretin; Adalimumab; Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Cyclosporine; Dermatologic Agents; Etanercept; Humans; Immunoglobulin G; Immunosuppressive Agents; Infliximab; Male; Melanoma; Methotrexate; Psoriasis; Receptors, Tumor Necrosis Factor; Severity of Illness Index; Skin Neoplasms; Treatment Outcome; Tumor Necrosis Factor-alpha | 2012 |
Patient-reported reasons for the discontinuation of commonly used treatments for moderate to severe psoriasis.
Topics: Acitretin; Adalimumab; Adult; Anti-Inflammatory Agents; Antibodies, Monoclonal, Humanized; Cross-Sectional Studies; Etanercept; Female; Humans; Immunoglobulin G; Immunosuppressive Agents; Keratolytic Agents; Logistic Models; Male; Methotrexate; Middle Aged; Patient Satisfaction; Psoriasis; PUVA Therapy; Receptors, Tumor Necrosis Factor; Surveys and Questionnaires; Treatment Outcome | 2013 |
Combination of adalimumab with traditional systemic antipsoriatic drugs - a report of 39 cases.
Topics: Acitretin; Adalimumab; Adult; Aged; Anti-Inflammatory Agents; Antibodies, Monoclonal, Humanized; Cyclosporine; Dermatologic Agents; Drug Therapy, Combination; Female; Humans; Immunosuppressive Agents; Keratolytic Agents; Male; Methotrexate; Middle Aged; Psoriasis; Treatment Outcome; Young Adult | 2012 |
Effectiveness of systemic treatment agents on psoriatic nails: a comparative study.
Topics: Acitretin; Adalimumab; Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Biological Factors; Combined Modality Therapy; Dermatologic Agents; Etanercept; Female; Humans; Immunoglobulin G; Infliximab; Keratolytic Agents; Male; Methotrexate; Middle Aged; Nail Diseases; Nails; Onycholysis; Phototherapy; Psoriasis; Receptors, Tumor Necrosis Factor | 2013 |
Risk of adverse events in psoriasis patients receiving classic systemic drugs and biologics in a 5-year observational study of clinical practice: 2008-2013 results of the Biobadaderm registry.
Topics: Acitretin; Adalimumab; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Biological Products; Cyclosporine; Etanercept; Female; Humans; Immunoglobulin G; Immunosuppressive Agents; Infliximab; Keratolytic Agents; Male; Methotrexate; Middle Aged; Proportional Hazards Models; Prospective Studies; Psoriasis; Receptors, Tumor Necrosis Factor; Registries; Risk Assessment; Spain; Ustekinumab | 2015 |
Frequency of monoclonal gammopathy in psoriatic patients receiving anti-TNF therapy compared with patients taking conventional drugs: a cross-sectional study.
Topics: Acitretin; Adalimumab; Adult; Age Factors; Aged; Anti-Inflammatory Agents, Non-Steroidal; Cross-Sectional Studies; Cyclosporine; Etanercept; Female; Humans; Immunosuppressive Agents; Infliximab; Keratolytic Agents; Male; Methotrexate; Middle Aged; Monoclonal Gammopathy of Undetermined Significance; Prevalence; Psoriasis; Tumor Necrosis Factor-alpha | 2015 |
Generalized eruptive keratoacanthoma: a diagnostic and therapeutic challenge.
Topics: Acitretin; Aged; Cyclophosphamide; Dermatologic Agents; Drug Therapy, Combination; Facial Dermatoses; Female; Humans; Immunosuppressive Agents; Keratoacanthoma; Keratolytic Agents; Male; Methotrexate; Middle Aged; Neck; Retreatment; Torso; Treatment Failure | 2015 |
Comparative effectiveness of less commonly used systemic monotherapies and common combination therapies for moderate to severe psoriasis in the clinical setting.
Topics: Acitretin; Adalimumab; Adult; Aged; Anti-Inflammatory Agents; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Cross-Sectional Studies; Cyclosporine; Dermatologic Agents; Drug Therapy, Combination; Etanercept; Female; Humans; Immunoglobulin G; Infliximab; Keratolytic Agents; Male; Methotrexate; Middle Aged; Psoriasis; Receptors, Tumor Necrosis Factor; Severity of Illness Index; Young Adult | 2014 |
A comparative study of histopathological findings in skin biopsies from patients with psoriasis before and after treatment with acitretin, methotrexate and phototherapy.
Topics: Acitretin; Adult; Biopsy; Female; Humans; Male; Methotrexate; Phototherapy; Psoriasis; Severity of Illness Index; Skin; Treatment Outcome | 2015 |
The 'switcher' patient profile in psoriasis treatment: from traditional to biological and from biological to traditional systemic drugs.
Topics: Acitretin; Adalimumab; Adult; Aged; Biological Factors; Cyclosporine; Dermatologic Agents; Drug Substitution; Etanercept; Female; Humans; Infliximab; Kaplan-Meier Estimate; Male; Methotrexate; Middle Aged; Psoriasis; Ustekinumab; Young Adult | 2015 |
How are we using systemic drugs to treat psoriasis in children? An insight into current clinical U.K. practice.
Topics: Acitretin; Adolescent; Child; Child, Preschool; Cyclosporine; Dapsone; Dermatologic Agents; Fumarates; Humans; Immunosuppressive Agents; Methotrexate; Practice Patterns, Physicians'; Psoriasis; United Kingdom | 2015 |
Cutaneous Rosai-Dorfman Disease Located on the Breast: Rapid Effectiveness of Methotrexate After Failure of Topical Corticosteroids, Acitretin and Thalidomide.
Topics: Acitretin; Administration, Cutaneous; Aged; Anti-Inflammatory Agents; Breast Diseases; Clobetasol; Dermatologic Agents; Female; Histiocytosis, Sinus; Humans; Immunosuppressive Agents; Keratolytic Agents; Methotrexate; Retreatment; Skin Diseases; Thalidomide; Treatment Failure | 2015 |
Systemic antipsoriatic combination therapy with fumaric acid esters for plaque-type psoriasis: report on 17 cases.
Topics: Acitretin; Adult; Aged; Anti-Inflammatory Agents; Cyclosporine; Dermatologic Agents; Drug Therapy, Combination; Etanercept; Female; Fumarates; Germany; Humans; Infliximab; Isoxazoles; Keratolytic Agents; Leflunomide; Male; Methotrexate; Middle Aged; Prednisolone; Psoriasis; Retrospective Studies | 2015 |
Factors associated with drug survival of methotrexate and acitretin in patients with psoriasis.
Topics: Acitretin; Administration, Oral; Adult; Age Factors; Aged; Arthritis, Psoriatic; Databases, Factual; Dermatologic Agents; Drug Prescriptions; Female; Folic Acid; Humans; Israel; Kaplan-Meier Estimate; Keratolytic Agents; Male; Medication Adherence; Metabolic Syndrome; Methotrexate; Middle Aged; Psoriasis | 2015 |
Essential Truths for the Care and Management of Moderate-to-Severe Psoriasis.
Topics: Acitretin; Adalimumab; Attitude of Health Personnel; Biological Products; Cyclosporine; Dermatologic Agents; Etanercept; Humans; Infliximab; Methotrexate; Perception; Practice Patterns, Physicians'; Psoriasis | 2015 |
Biologic and Conventional Systemic Therapies Show Similar Safety and Efficacy in Elderly and Adult Patients With Moderate to Severe Psoriasis.
Topics: Acitretin; Adalimumab; Adolescent; Adult; Aged; Antibodies, Monoclonal; Biological Products; Certolizumab Pegol; Cyclosporine; Dermatologic Agents; Drug Prescriptions; Drug Therapy, Combination; Etanercept; Female; Humans; Infliximab; Male; Methotrexate; Middle Aged; Practice Patterns, Physicians'; Psoriasis; Retrospective Studies; Severity of Illness Index; Ultraviolet Therapy; Ustekinumab; Young Adult | 2015 |
European S3-Guidelines on the systemic treatment of psoriasis vulgaris--Update 2015--Short version--EDF in cooperation with EADV and IPC.
Topics: Acitretin; Adalimumab; Anti-Inflammatory Agents, Non-Steroidal; Cyclosporine; Drug Therapy, Combination; Etanercept; Fumarates; Humans; Immunosuppressive Agents; Keratolytic Agents; Methotrexate; Psoriasis; Ustekinumab | 2015 |
Algorithm to select optimal systemic anti-psoriatic drugs in relation with patients' Psoriasis Area and Severity Index score for plaque psoriasis.
Topics: Acitretin; Adolescent; Adult; Aged; Algorithms; Cyclosporine; Dermatologic Agents; Female; Humans; Male; Methotrexate; Middle Aged; Psoriasis; Retrospective Studies; Severity of Illness Index; Treatment Outcome; Young Adult | 2016 |
Systemic treatments in childhood psoriasis: a French multicentre study on 154 children.
Topics: Acitretin; Adolescent; Child; Child, Preschool; Cyclosporine; Dermatologic Agents; France; Humans; Immunosuppressive Agents; Keratolytic Agents; Methotrexate; Phototherapy; Psoriasis; Treatment Outcome | 2016 |
Methotrexate versus Acitretin in the Treatment of Chronic Hand Dermatitis.
Topics: Acitretin; Adult; Aged; Chronic Disease; Dermatologic Agents; Female; Hand Dermatoses; Humans; Keratolytic Agents; Male; Methotrexate; Middle Aged | 2015 |
Retrospective analysis of the effectiveness and costs of traditional treatments for moderate-to-severe psoriasis: A single-center, Italian study.
Topics: Acitretin; Adult; Cyclosporine; Dermatologic Agents; Female; Humans; Italy; Male; Methotrexate; Middle Aged; Phototherapy; Psoriasis; Retrospective Studies; Treatment Outcome | 2016 |
[Cost Effectiveness of Treatments of Psoriasis with a PASI 75 and one Period of 12 Weeks].
Topics: Acitretin; Adalimumab; Cost-Benefit Analysis; Cyclosporine; Etanercept; Health Care Costs; Humans; Immunosuppressive Agents; Infliximab; Methotrexate; Models, Economic; Psoriasis; PUVA Therapy; Severity of Illness Index; Spain; Time Factors; Treatment Outcome; Ultraviolet Therapy; Ustekinumab | 2016 |
Generalized pustular psoriasis treated with ustekinumab.
Topics: Acitretin; Adalimumab; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Cyclosporine; Drug Resistance; Female; Humans; Immunosuppressive Agents; Keratolytic Agents; Methotrexate; Psoriasis; Skin Diseases, Vesiculobullous; Treatment Outcome; Ustekinumab | 2016 |
[Effect of acitretin and methotrexate on treatment of
severe plaque psoriasis].
Topics: Acitretin; Humans; Methotrexate; Psoriasis | 2016 |
Efficacy, safety and drug survival of conventional agents in pediatric psoriasis: A multicenter, cohort study.
Topics: Acitretin; Adolescent; Child; Cohort Studies; Cyclosporine; Dermatologic Agents; Female; Humans; Male; Methotrexate; Psoriasis; Treatment Outcome | 2017 |
Biologic drug survival in Israeli psoriasis patients.
Topics: Acitretin; Adalimumab; Adult; Databases, Factual; Dermatologic Agents; Drug Substitution; Drug Therapy, Combination; Drug Tolerance; Etanercept; Female; Humans; Immunosuppressive Agents; Infliximab; Interleukin-12 Receptor beta 1 Subunit; Israel; Male; Metabolic Syndrome; Methotrexate; Middle Aged; Psoriasis; Time Factors; Tumor Necrosis Factor-alpha; Ustekinumab | 2017 |
Characteristics and risk profile of psoriasis patients included in the Czech national registry BIOREP and a comparison with other registries.
Topics: Acitretin; Adult; Biological Products; Body Mass Index; Comorbidity; Coronary Disease; Cyclosporine; Czech Republic; Dermatologic Agents; Diabetes Mellitus; Female; Humans; Hyperlipidemias; Hypertension; Keratolytic Agents; Male; Methotrexate; Middle Aged; Obesity; Phototherapy; Prevalence; Psoriasis; Quality of Life; Registries; Retreatment; Retrospective Studies; Risk Factors; Severity of Illness Index | 2017 |
Management of patients with psoriasis.
Topics: Acitretin; Administration, Cutaneous; Anti-Inflammatory Agents; Betamethasone; Calcitriol; Cyclosporine; Dermatologic Agents; Disease Management; Emollients; Humans; Immunosuppressive Agents; Keratolytic Agents; Methotrexate; Phototherapy; Psoriasis; Thalidomide | 2017 |
The acitretin and methotrexate combination therapy for psoriasis vulgaris achieves higher effectiveness and less liver fibrosis.
Topics: Acitretin; Animals; Cells, Cultured; Dermatologic Agents; Drug Therapy, Combination; Humans; Keratolytic Agents; Liver; Liver Cirrhosis; Male; Methotrexate; Mice; Psoriasis; Skin | 2017 |
Palmoplantar pustulosis - a cross-sectional analysis in Germany.
Topics: Acitretin; Adrenal Cortex Hormones; Adult; Age of Onset; Arthritis, Psoriatic; Body Mass Index; Comorbidity; Cross-Sectional Studies; Dermatologic Agents; Female; Germany; Humans; Keratolytic Agents; Male; Methotrexate; Middle Aged; Psoriasis; Quality of Life; Severity of Illness Index; Smoking; Ultraviolet Therapy; Young Adult | 2017 |
Biologics combined with conventional systemic agents or phototherapy for the treatment of psoriasis: real-life data from PSONET registries.
Topics: Acitretin; Adalimumab; Austria; Biological Products; Combined Modality Therapy; Cyclosporine; Czech Republic; Dermatologic Agents; Drug Therapy, Combination; Etanercept; Female; Fumarates; Humans; Infliximab; Israel; Italy; Kaplan-Meier Estimate; Male; Methotrexate; Middle Aged; Netherlands; Psoriasis; PUVA Therapy; Registries; Severity of Illness Index; Ustekinumab | 2018 |
Drug utilization patterns and adherence in patients on systemic medications for the treatment of psoriasis: A retrospective, comparative cohort study.
Topics: Acitretin; Adalimumab; Adolescent; Adult; Aged; Biological Products; Drug Utilization; Etanercept; Female; Humans; Immunosuppressive Agents; Male; Medication Adherence; Methotrexate; Middle Aged; Propensity Score; Psoriasis; Retrospective Studies; Treatment Outcome; Ustekinumab; Young Adult | 2018 |
Chronic hand eczema in Germany: 5-year follow-up data from the CARPE registry.
Topics: Acitretin; Administration, Cutaneous; Adolescent; Adrenal Cortex Hormones; Adult; Aged; Aged, 80 and over; Alitretinoin; Chronic Disease; Dermatitis, Allergic Contact; Dermatologic Agents; Eczema; Female; Follow-Up Studies; Hand Dermatoses; Humans; Male; Methotrexate; Middle Aged; Outcome Assessment, Health Care; Patient Reported Outcome Measures; PUVA Therapy; Registries; Ultraviolet Therapy; Urea; Young Adult | 2019 |
Systemic Treatment of Moderate to Severe Psoriasis in Pediatric Patients in Galicia, Spain: A Descriptive Study.
Topics: Acitretin; Adolescent; Child; Comorbidity; Cross-Sectional Studies; Drug Utilization; Humans; Methotrexate; Phototherapy; Procedures and Techniques Utilization; Psoriasis; Spain | 2018 |
Calcipotriol plus betamethasone dipropionate aerosol foam vs. apremilast, methotrexate, acitretin or fumaric acid esters for the treatment of plaque psoriasis: a matching-adjusted indirect comparison.
Topics: Acitretin; Administration, Cutaneous; Aerosols; Betamethasone; Calcitriol; Dermatologic Agents; Drug Therapy, Combination; Esters; Female; Fumarates; Humans; Male; Methotrexate; Middle Aged; Psoriasis; Thalidomide; Treatment Outcome | 2019 |
Ocular findings in patients with psoriasis: is it related to the side effects of treatment or to psoriasis itself? A case-control study.
Topics: Acitretin; Adult; Case-Control Studies; Dermatologic Agents; Dry Eye Syndromes; Female; Humans; Logistic Models; Male; Methotrexate; Middle Aged; Odds Ratio; Prospective Studies; Psoriasis; Young Adult | 2020 |
Low dose acitretin versus methotrexate in the treatment of palmoplantar psoriasis: a case series.
Topics: Acitretin; Aged; Dermatologic Agents; Dose-Response Relationship, Drug; Female; Humans; Male; Methotrexate; Middle Aged; Psoriasis | 2019 |
Acitretin-induced curling of hair in a Korean male.
Topics: Acitretin; Administration, Oral; Asian People; Drug Substitution; Hair; Humans; Keratolytic Agents; Male; Methotrexate; Middle Aged; Nail Diseases; Psoriasis; Republic of Korea; Treatment Outcome | 2019 |
Drug survival of conventional systemic and biologic therapies for moderate-to-severe psoriasis in clinical practice in Spain: prospective results from the SAHARA study.
Topics: Acitretin; Adalimumab; Adolescent; Adult; Age of Onset; Biological Products; Cyclosporine; Dermatologic Agents; Etanercept; Female; Humans; Kaplan-Meier Estimate; Male; Methotrexate; Middle Aged; Proportional Hazards Models; Prospective Studies; Psoriasis; Spain; Ustekinumab | 2020 |
Lp-PLA2 as a promising predictor of comorbidities in patients with severe psoriasis.
Topics: 1-Alkyl-2-acetylglycerophosphocholine Esterase; Acitretin; Adult; Aged; Aged, 80 and over; Biomarkers; Case-Control Studies; Female; Humans; Keratolytic Agents; Male; Methotrexate; Middle Aged; Obesity; Psoriasis; Risk Factors; Young Adult | 2020 |
Changes in serum TNF-like weak inducer of apoptosis (TWEAK) levels and Psoriasis Area Severity Index (PASI) scores in plaque psoriasis patients treated with conventional versus anti-TNF treatments.
Topics: Acitretin; Adalimumab; Adult; Anti-Inflammatory Agents; Cyclosporine; Cytokine TWEAK; Dermatologic Agents; Etanercept; Female; Humans; Infliximab; Keratolytic Agents; Male; Methotrexate; Middle Aged; Psoriasis; Severity of Illness Index; Tumor Necrosis Factor-alpha | 2020 |
Synthesis and in vitro cytotoxicity evaluation of star-shaped polymethacrylic conjugates with methotrexate or acitretin as potential antipsoriatic prodrugs.
Topics: Acitretin; Apoptosis; Cell Cycle; Cell Line, Tumor; Chemistry Techniques, Synthetic; Dose-Response Relationship, Drug; Humans; Methotrexate; Polymethacrylic Acids; Psoriasis; Skin | 2020 |
Verrucous psoriasis treated with methotrexate and acitretin combination therapy.
Topics: Acitretin; Aged; Dermatologic Agents; Drug Therapy, Combination; Female; Humans; Keratolytic Agents; Methotrexate; Psoriasis | 2019 |
Joint American Academy of Dermatology-National Psoriasis Foundation guidelines of care for the management of psoriasis with systemic nonbiologic therapies.
Topics: Acitretin; Cyclosporine; Drug Monitoring; Humans; Methotrexate; Piperidines; Psoriasis; Pyrimidines; Thalidomide | 2020 |
Treatment of pityriasis rubra pilaris: a case series of 28 patients.
Topics: Acitretin; Biological Products; Cyclosporine; Dermatologic Agents; Drug Therapy, Combination; Female; Humans; Infliximab; Male; Methotrexate; Middle Aged; Pityriasis Rubra Pilaris; Retrospective Studies; Smoking; Ustekinumab | 2020 |
Planifier une grossesse chez une patiente avec un psoriasis.
Topics: Acitretin; Contraindications, Drug; Dermatologic Agents; Female; Fertility; Humans; Male; Methotrexate; Patient Care Planning; Preconception Care; Pregnancy; Pregnancy Complications; Psoriasis | 2020 |
Le choix thérapeutique : médicaments du psoriasis et grossesse avant, pendant et après la grossesse.
Topics: Acitretin; Biological Factors; Breast Feeding; Contraindications, Drug; Cyclosporine; Dermatologic Agents; Female; Humans; Immunosuppressive Agents; Methotrexate; Pregnancy; Pregnancy Complications; Pregnancy Complications, Infectious; Psoriasis; Risk Factors; Ultraviolet Therapy | 2020 |
Immune checkpoint-mediated psoriasis: A multicenter European study of 115 patients from the European Network for Cutaneous Adverse Event to Oncologic Drugs (ENCADO) group.
Topics: Acitretin; Aged; Biological Products; Dermatologic Agents; Drug Therapy, Combination; Europe; Female; Follow-Up Studies; Glucocorticoids; Humans; Immune Checkpoint Inhibitors; Male; Methotrexate; Middle Aged; Neoplasms; Psoriasis; Retrospective Studies; Severity of Illness Index; Thalidomide; Treatment Outcome | 2021 |
Safety of the combined use of methotrexate and acitretin in a dermatology hospital setting.
Topics: Acitretin; Adult; Aged; Chemical and Drug Induced Liver Injury; Dermatologic Agents; Drug Therapy, Combination; Female; Humans; Male; Methotrexate; Middle Aged; Skin Diseases | 2021 |
The potential impact of systemic anti-inflammatory therapies in psoriasis on major adverse cardiovascular events: a Korean nationwide cohort study.
Topics: Acitretin; Adult; Aged; Anti-Inflammatory Agents; Cardiovascular Diseases; Cyclosporine; Female; Humans; Incidence; Male; Methotrexate; Middle Aged; Phototherapy; Proportional Hazards Models; Psoriasis; Republic of Korea; Severity of Illness Index; Young Adult | 2021 |
Psoriasis: a brief overview.
Topics: Acitretin; Humans; Immunosuppressive Agents; Methotrexate; Phototherapy; Psoriasis | 2021 |
Incidence and Risk Factors of Hepatic Fibrosis in Psoriatic Patients Receiving Methotrexate with Concomitant Acitretin Therapy and Methotrexate Monotherapy.
Topics: Acitretin; Cohort Studies; Drug Therapy, Combination; Humans; Liver Cirrhosis; Methotrexate; Psoriasis; Retrospective Studies; Risk Factors | 2021 |
A case of psoriasis successfully treated by extracorporeal photopheresis during COVID-19 pandemic.
Topics: Acitretin; Chemical and Drug Induced Liver Injury; Combined Modality Therapy; Contraindications, Drug; COVID-19; Cyclosporine; Humans; Lymphoma, Non-Hodgkin; Male; Methotrexate; Middle Aged; Nails; Pandemics; Photopheresis; Psoriasis; Quality of Life; SARS-CoV-2; Severity of Illness Index; Ultraviolet Therapy | 2021 |
Anti-IL23for nail psoriasis in real life: Results of efficacy and safety during a 52-week period.
Topics: Acitretin; Humans; Methotrexate; Nail Diseases; Psoriasis; Quality of Life; Treatment Outcome | 2022 |
Combined acitretin-methotrexate therapy seems safe and efficient in children with psoriasis.
Topics: Acitretin; Child; Dermatologic Agents; Drug Therapy, Combination; Humans; Keratolytic Agents; Methotrexate; Psoriasis; Treatment Outcome | 2022 |
Biologics combined with conventional systemic agents for the treatment of children with severe psoriasis. Real-life data from the BiPe cohorts and a practice survey among French and Italian pediatric dermatologists.
Topics: Acitretin; Adalimumab; Biological Products; Child; Dermatologic Agents; Dermatologists; Etanercept; Humans; Methotrexate; Psoriasis; Treatment Outcome; Tumor Necrosis Factor Inhibitors | 2022 |
Conventional therapy in psoriasis. Lost in translation?
Topics: Acitretin; Cohort Studies; Cyclosporine; Fumarates; Humans; Methotrexate; Psoriasis | 2023 |
Effectiveness and persistence of acitretin, ciclosporin, fumaric acid esters and methotrexate for patients with moderate-to-severe psoriasis: a cohort study from BADBIR.
Topics: Acitretin; Adjuvants, Immunologic; Biological Factors; Cohort Studies; Cyclosporine; Dermatologic Agents; Fumarates; Humans; Immunologic Factors; Male; Methotrexate; Prospective Studies; Psoriasis; Treatment Outcome | 2023 |
The real-world effectiveness and persistence of acitretin, ciclosporin, fumaric acid esters and methotrexate for treating moderate-to-severe psoriasis.
Topics: Acitretin; Cohort Studies; Cyclosporine; Fumarates; Humans; Methotrexate; Psoriasis | 2023 |